Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled single and multiple ascending dose study of OCR-002 in healthy volunteers
NL-OMON34455Active, not recruiting
- Sponsor
- Ocera Therapeutics
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in fulminant hepatitis comparing OCR-002 with Placebo (2 arms). Primary endpoints: Plasma OCR-002 pharmacokinetics and Safety and tolerability. Started May 2010; status: active, not recruiting.
02
Drugs
ornithine phenylacetate
03
Conditions
fulminant hepatitis
Beyond the preview
Go deeper on NL-OMON34455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34455.